Salemonline Journal

Primary Myelofibrosis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032),| Key Companies – Novartis, CTI Biopharmaceuticals, AbbVie Bristol Myers Squibb, Gale

 Breaking News
  • No posts were found

Primary Myelofibrosis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032),| Key Companies – Novartis, CTI Biopharmaceuticals, AbbVie Bristol Myers Squibb, Gale

May 01
20:16 2023
Primary Myelofibrosis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032),| Key Companies - Novartis, CTI Biopharmaceuticals, AbbVie Bristol Myers Squibb, Gale
DelveInsight Business Research LLP
DelveInsight’s “Primary Myelofibrosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Primary Myelofibrosis, historical and forecasted epidemiology as well as the Primary Myelofibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “Primary Myelofibrosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Primary Myelofibrosis, historical and forecasted epidemiology as well as the Primary Myelofibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. 

 Primary Myelofibrosis Overview

Primary Myelofibrosis is a rare disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. It is classified as a type of chronic leukemia and belongs to a group of blood disorders called myeloproliferative diseases. Over time, this leads to progressive bone marrow failure. Under normal conditions, the bone marrow provides a fine network of fibers on which the stem cells can divide and grow. Specialized cells in the bone marrow, known as fibroblasts, make these fibers. Myelofibrosis can be of two types primary myelofibrosis and secondary myelofibrosis. Due to a shortage of red blood cells, myelofibrosis symptoms include extreme tiredness (fatigue) or shortness of breath, whereas the loss of white blood cells can lead to an increased number of infections, and a reduction of platelets can cause easy bleeding or bruising.

 

Primary Myelofibrosis Epidemiology Insights

  • In the countries of the European Union, the incidence of myelofibrosis ranges from a low of 0.3 per 100,000 persons to a high of 1.9 per 100,000 persons, with an average incidence of 1.1 per 100,000 persons.

  • In Olmsted County, Minnesota, USA, the annual incidence of primary myelofibrosis (PMF) is 1.33 per 100,000.

  • The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide.

  • In developed countries, the prevalence of myelofibrosis ranges from 0.5 per 100,000 per year to 9 per 100,000 per year.

  • Myelofibrosis is a disease that tends to affect the middle-aged and elderly population. The mean age at diagnosis is 60 years.

Click here to learn more about the Primary Myelofibrosis Market Landscape

The Report Covers the Primary Myelofibrosis Epidemiology Segmented by:

  • Total Primary Myelofibrosis incident cases  

  • Total Primary Myelofibrosis diagnosed cases 

  • Total Primary Myelofibrosis prevalent cases 

  • Total Primary Myelofibrosis treatment cases 

Primary Myelofibrosis Market Outlook 

The Primary Myelofibrosis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Primary Myelofibrosis market trends by analyzing the impact of current Primary Myelofibrosis therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Primary Myelofibrosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Primary Myelofibrosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Primary Myelofibrosis market in 7MM is expected to witness a major change in the study period 2019-2032.

 Key Companies Working in the Primary Myelofibrosis Market

  • Novartis 

  • CTI Biopharmaceuticals 

  • AbbVie 

  • Bristol Myers Squibb 

  • Galecto Bio AB 

And many others 

Primary Myelofibrosis Therapies Covered and Analyzed in the Report:

  • INC424

  • BKM120

  • Ruxolitinib

  • Pacritinib

  • PXS-5505

And many others 

Learn more about the Key Companies and Emerging Therapies in the Primary Myelofibrosis Market

Table of Contents 

  1. Key Insights 

  2. Primary Myelofibrosis Introduction 

  3. Executive Summary of Primary Myelofibrosis  

  4. Disease Background and Overview

  5. Epidemiology and patient population

  6. Primary Myelofibrosis Emerging Therapies

  7. Primary Myelofibrosis Market Outlook

  8. Market Access and Reimbursement of Therapies

  9. Market Drivers 

  10. Market Barriers 

  11. Appendix

  12. Report Methodology

  13. DelveInsight Capabilities

  14. Disclaimer

Learn about the detailed offerings of the report @ Primary Myelofibrosis Market Outlook

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting